Assessment of STAT5 as a potential therapy target in enzalutamide-resistant prostate cancer-Reference-Cited by-同舟云学术

Assessment of STAT5 as a potential therapy target in enzalutamide-resistant prostate cancer

Published:2020-08-13 Issue:8 Volume:15 Page:e0237248
ISSN:1932-6203
Container-title:PLOS ONE
language:en
Short-container-title:PLoS ONE

Author:

Erb Holger H. H.^ORCID,Bodenbender Julia,Handle Florian,Diehl Tamara,Donix Lukas,Tsaur Igor,Gleave Martin,Haferkamp Axel,Huber Johannes,Fuessel Susanne,Juengel Eva,Culig Zoran,Thomas Christian

Funder

ASTELLAS grant

Publisher

Public Library of Science (PLoS)

Subject

Multidisciplinary

Reference65 articles.

1. Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012;J Ferlay;Int J Cancer,2015

2. Estimating the global cancer incidence and mortality in 2018: GLOBOCAN sources and methods;J Ferlay;International journal of cancer,2019

3. Challenges to improved therapeutics for metastatic castrate resistant prostate cancer: from recent successes and failures;X Huang;J Hematol Oncol,2012

4. Enzalutamide for the treatment of metastatic castration-resistant prostate cancer;A Rodriguez-Vida;Drug Des Devel Ther,2015

5. Enzalutamide in Men with Nonmetastatic, Castration-Resistant Prostate Cancer;M Hussain;The New England journal of medicine,2018

Cited by 15 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Prostate Cancer’s Silent Partners: Fibroblasts and Their Influence on Glutamine Metabolism Manipulation;International Journal of Molecular Sciences;2024-08-27

2. Emerging frontiers in androgen receptor research for prostate Cancer: insights from the 2nd international androgen receptor Symposium;Journal of Experimental & Clinical Cancer Research;2024-07-17

3. Modulation of the Prostate Cancer Resistance Factor Hsp27 by the Chemotherapeutic Drugs Abiraterone, Cabazitaxel, Docetaxel and Enzalutamide;Anticancer Research;2024-06-26

4. Breaking through resistance in mCRPC: Enzalutamide analogues as effective anticancer agents for enhanced male survival;Results in Chemistry;2023-12

5. Stat5 inhibits NLRP3‐mediated pyroptosis to enhance chemoresistance of breast cancer cells via promoting miR‐182 transcription;Chemical Biology & Drug Design;2023-04-18